PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2128119
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2128119
The global digital biomanufacturing market was valued at USD 22.44 billion in 2025 and is projected to grow to USD 25.16 billion in 2026. The market is expected to reach USD 66.14 billion by 2034, expanding at a CAGR of 12.84% during the forecast period. The increasing production of biologics, biosimilars, vaccines, cell therapies, and gene therapies, coupled with rising demand for automation and digital process optimization, is driving market expansion. In 2025, North America dominated the digital biomanufacturing market, accounting for 41.27% of the global market share.
Digital biomanufacturing combines automation, connected equipment, process analytics, manufacturing execution systems (MES), electronic batch records (eBR), artificial intelligence, and real-time monitoring to optimize biologics manufacturing. The growing adoption of single-use technologies, increasing outsourcing to contract development and manufacturing organizations (CDMOs), and the transition from paper-based documentation to connected digital workflows continue to accelerate market growth worldwide.
Market Trends
A major trend in the digital biomanufacturing market is the growing adoption of automation and real-time process control. Biopharmaceutical manufacturers are replacing manual production methods with integrated digital platforms capable of monitoring critical process parameters such as pH, dissolved oxygen, temperature, pressure, and feed rates in real time.
The integration of SCADA systems, distributed control systems (DCS), process analytical technology (PAT), cloud platforms, and AI-driven monitoring tools is improving manufacturing consistency, reducing batch failures, and accelerating technology transfer across development and commercial production facilities.
Market Drivers
The rapid expansion of biologics, biosimilars, vaccines, recombinant proteins, cell therapies, and gene therapies remains the primary growth driver for the digital biomanufacturing market. Unlike conventional pharmaceutical manufacturing, biologics production requires highly controlled, data-intensive manufacturing environments with strict regulatory compliance.
Digital manufacturing platforms help reduce manual errors, improve batch consistency, simplify regulatory documentation, accelerate process scale-up, and enhance technology transfer across multiple manufacturing sites. Increasing investments by CDMOs and biopharmaceutical companies in advanced manufacturing facilities continue supporting strong market growth.
Market Restraints
High implementation costs remain a major challenge for digital biomanufacturing adoption. Deploying integrated digital manufacturing systems requires significant investments in automation infrastructure, MES, electronic batch records, process analytical technologies, cybersecurity, data integration, validation, employee training, and ongoing technical support.
Smaller biotechnology companies and regional manufacturers often adopt digital technologies gradually because of budget limitations and the complexity of integrating modern platforms with existing legacy systems.
Market Opportunities
Growing regulatory support for advanced pharmaceutical manufacturing presents significant growth opportunities for the industry. Regulatory agencies increasingly encourage the adoption of automation, digital twins, robotics, AI, and real-time monitoring technologies that improve manufacturing consistency and product quality.
The increasing commercialization of advanced therapies, including cell and gene therapies, is creating strong demand for digitally connected manufacturing platforms capable of delivering scalable, validated, and regulatory-compliant production environments.
Market Challenges
A shortage of skilled professionals with expertise in both bioprocess engineering and digital manufacturing technologies remains one of the industry's key challenges. Successful implementation requires specialists experienced in automation, artificial intelligence, MES, process analytical technology, data integration, validation, cybersecurity, and quality management.
The limited availability of qualified personnel increases implementation costs, delays deployment schedules, and slows the realization of productivity improvements following digital investments.
Based on offering, the hardware and connected equipment segment dominated the market in 2025 due to substantial investments in automated bioreactors, connected single-use systems, and integrated manufacturing equipment. Meanwhile, the services segment is expected to witness the fastest growth as companies increasingly require consulting, validation, system integration, and technical support.
By type, the automation and process control segment holds the largest market share because biologics manufacturing depends heavily on continuous monitoring and control of critical production parameters. The AI, machine learning, and advanced analytics segment is projected to record the highest growth throughout the forecast period.
According to application, commercial GMP manufacturing execution remains the dominant segment as manufacturers increasingly adopt paperless batch records, automated production workflows, and regulatory-compliant manufacturing systems. Technology transfer and facility digitalization are also expanding rapidly as companies modernize production facilities.
By end user, pharmaceutical and biotechnology companies account for the largest market share due to significant investments in biologics manufacturing capacity, digital transformation, and global production expansion. Contract manufacturing organizations (CMOs) and CDMOs are also experiencing strong demand as outsourcing continues to grow.
North America led the global digital biomanufacturing market in 2025, generating USD 9.26 billion in revenue. The region benefits from extensive biologics manufacturing capacity, advanced automation technologies, strong regulatory support, and widespread adoption of digital manufacturing platforms. The U.S. market is projected to reach USD 9.42 billion in 2026, representing approximately 37.5% of global revenue.
Europe remains the second-largest market, supported by established biologics manufacturing infrastructure, increasing adoption of digital manufacturing systems, and favorable regulatory policies.
Asia Pacific is expected to experience the fastest growth, reaching USD 5.70 billion in 2026. Rapid expansion of biologics manufacturing, CDMO capacity, vaccines, biosimilars, and advanced therapies across China, India, Japan, South Korea, Singapore, and Australia continues driving regional demand.
Meanwhile, Latin America and the Middle East & Africa are witnessing steady market expansion through increasing investments in pharmaceutical manufacturing, healthcare infrastructure, and local biologics production.
Competitive Landscape
The digital biomanufacturing market remains moderately fragmented, with major companies focusing on integrated automation platforms, cloud-based manufacturing systems, AI-driven analytics, digital twins, and connected laboratory informatics. Leading industry participants include Siemens, Sartorius AG, Danaher Corporation (Cytiva), Emerson Electric Co., Korber AG, Aspen Technology, Benchling, TetraScience, Schneider Electric, and Rockwell Automation. Strategic partnerships, portfolio expansion, and technological innovation continue to strengthen competitive positioning across the global market.
Conclusion
The global digital biomanufacturing market is expected to grow significantly from USD 22.44 billion in 2025 to USD 25.16 billion in 2026, reaching USD 66.14 billion by 2034. Increasing production of biologics, biosimilars, vaccines, and advanced therapies, together with rising adoption of automation, artificial intelligence, and connected manufacturing systems, will continue driving market growth. Although implementation costs and workforce shortages remain key challenges, ongoing technological advancements, regulatory support, and expanding digital transformation across biopharmaceutical manufacturing are expected to create substantial long-term growth opportunities throughout the forecast period.
Segmentation By Offering, Type, Application, End User, and Region
By Offering * Software & Platforms
By Type * Manufacturing Execution & Electronic Batch Records
By Application * Process Development & Scale-up
By End User * Pharmaceuticals & Biotechnology Companies
By Region * North America (By Offering, Type, Application, End User, and Country)